{"entity":{"id":"opb-101","kind":"drug","name":"OPB-101","aka":[],"tldr":"OPB-101 is an experimental autologous CAR T-cell therapy from Outpace Bio, in phase 1 trials for platinum-resistant ovarian cancer; its current status is not stated.","summary":"OPB-101 is an autologous CAR T-cell therapy from Outpace Bio. Autologous mesothelin CAR T cells that switch on a designed IL-2 cytokine (OUTSMART) only when they meet the target antigen. Its furthest stage is phase 1, for platinum-resistant ovarian cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT07030907 terminated, reason \"Business decision\"; OPB-101 is no longer on the company pipeline page (checked 3 Nov 2026). No source states it is discontinued. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Outpace Bio: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07030907"},{"label":"Outpace Bio: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07030907"},{"label":"ClinicalTrials.gov: trials of OPB-101","url":"https://clinicaltrials.gov/search?intr=OPB-101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["platinum-resistant-ovarian-cancer"],"sections":[],"technologies":[],"targets":["mesothelin"],"drugs":[],"companies":["outpace-bio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07030907"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"OPB-101","modality":"Autologous CAR T-cell therapy","mechanism":"Autologous mesothelin CAR T cells that switch on a designed IL-2 cytokine (OUTSMART) only when they meet the target antigen.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/opb-101/","neighbours":{"cancer":[{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"target":[{"id":"mesothelin","kind":"target","name":"Mesothelin","route":"/targets/mesothelin/"}],"company":[{"id":"outpace-bio","kind":"company","name":"Outpace Bio","route":"/companies/outpace-bio/"}],"trial":[{"id":"nct07030907","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer","route":"/trials/nct07030907/"}]}}